$1.1M net raised for ARSACS research at the Diner des Producteurs
The Diner des Producteurs, an annual major fundraising event to support ARSACS research, was held on October 27, 2022 under the Honorary Presidency of Mr. Vincent Chiara.
On behalf of the persons living with ARSACS, their families and the Foundation, thank you to all of you for your generosity : Mr. Vincent Chiara, sponsors, partners, donors and volunteers. With your support, the Foundation can pursue its mission to develop a treatment for ARSACS.
Researchers & Pharmaceuticals
Apply for a grant
The Foundation provides grants and opportunities to researchers.The research grant could be as high as $100,000 for a 12 month period and could be renewed for a second year.
Research tools available
- Sacs Knock Out mouse (#033221)
- Sacs Knock In mouse (#033385)
- iPS cells derived from samples taken from people diagnosed with ARSACS (homozygous c.8844delT).
The Foundation organizes and supports conferences such as the International ARSACS Symposium.
Preclinical and clinical trials
The Foundation is looking for partners to conduct preclinical and clinical trials. It has the expertise and the tools available.
The Ataxia Charlevoix-Saguenay Foundation’s mission is to discover and develop a treatment for the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).
The Ataxia Charlevoix-Saguenay Foundation, founded in 2006, is a charitable organization federally registered with no employees and is supported entirely by private donations and volunteers
“Preclinical studies in the Sacs KO mouse model of ARSACS”– research project under the leadership of Dr Stefan Strack from University of Iowa, USA
Le Diner des Producteurs – Reservation form
As part of a program at improving worker health, Rio Tinto et 3 business companies from Saguenay donate $2,887.50 for ARSACS research. Thank you to the donors and the organizers for their generosity.
Photo from L to R, Mr. Etienne Fortin (Rio Tinto), Georges Perron (JE Perron), Carl Émond (Claveau et Fils), Jeannot Savard (Excavation de Chicoutimi Inc.), Gabriel Paquet (Défi Charlevoix-Saguenay) and Carl Bourgeois (representing the Ataxia Charlevoix-Saguenay Foundation).
“A mitochondrial-targeted antioxidant (MitoQ) improves motorcoordination and reduces Purkinje cell death in a mouse model”
“A mitochondrial-targeted antioxidant (MitoQ) improves motor coordination and reduces Purkinje cell death in a mouse model of ARSACS”– ARSACS research by Drs. Watt and McKinney from McGill published in the Neurobiology of Disease journal in May, 2023. Research funded by the Ataxia Charlevoix-Saguenay Foundation.
ARSACS research by Dr. Maltecca and her team published in the JCI insights in May, 2023. “Restoring calcium homeostasis in Purkinje cells arrests neurodegeneration and neuroinflammation in the ARSACS mouse model”
Join us for an unique opportunity to learn about the latest advancements in ARSACS research.
As an accredited satellite meeting of the 2023 World Congress of Neurology (WCN), the ARSACS Symposium will be held immediately following the WCN on October 19 -20 in Montreal. It is a free scientific in-person and virtual event open to all.
We hope to see you there!